Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-176

mate as I said earlier they are on a good wicket with plenty of cash on hand. They could potentially milk this company out for 5-10 years wages developing some indication on another drug. Would be the best case scenario for them. Ultimately 40% of the cash goes to corporate expenses over a 10 year period.

there is no way they’ll return cash to shareholders cause they don’t have enough interest in the company to do so. Best thing for them is to continue trading and last as long as possible.

after toms response I’m thinking of selling my holding. Opportunity cost elsewhere. They aren’t stupid, why else are they doing this review, why else did they announce TBI. IIH a potential dead duck thanks to ozempic. All IMO